The maintenance of B cell tolerance is dependent on cell surface molecules that serve to modulate signaling through the B cell receptor (BCR), such as Fc gamma receptor IIb (FcγRIIb; CD32b) and complement receptor (CR) 1 (CD35) and 2 (CD21). Consequently, deficiency in these receptors might lead to autoimmunity. We have studied the basal expression of FcγRIIb, CR1 and CR2 on B cells in healthy male and female blood donors in comparison to rheumatoid arthritis (RA) patients to reveal any possible differences. Firstly, we found a gender associated difference in FcγRIIb expression, as healthy women had lower basal expression of FcγRIIb on B cells than men and the expression significantly decreased with age.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterized by autoantibodies and chronic joint inflammation [1] . Like many other autoimmune diseases has RA a clear gender bias as women are more often affected than men and female sex hormones such as estrogen modulate the disease (reviewed in [2] ). Thus, increased estrogen levels as seen during pregnancy, are associated with amelioration of RA [3] , while reduced levels, as seen post partum or at menopause, are associated with disease flare or onset of RA [4; 5] . Furthermore, studies in collagen-induced arthritis (CIA), an animal model of RA, have shown that the disease can be suppressed by estrogen treatment and that estrogen influences the B cell response [6; 7] .
The involvement of B cells in RA pathology has been recognized. Thus, B cells can be found in infiltrates of the inflamed joints and removal of B cells by anti-CD20 depleting therapy results in improvement of the disease [8; 9]. In addition, specific autoantibodies such as rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibodies can be found years before disease onset, pointing towards an early break in B cell tolerance [10; 11].
For the generation and control of an appropriate B cell immune response, balanced signaling through regulatory receptors is important. The inhibitory Fc gamma receptor IIb (FcγRIIb; CD32b) is a low affinity receptor that binds antigen-bound IgG. When FcγRIIb is cross-linked with the B cell receptor (BCR) it reduces B cell activation and antibody production [12; 13; 14; 15]. The importance of FcγRIIb in peripheral B cell tolerance has been indicated in FcγRIIb-deficient mice, which on a specific genetic background develop spontaneous lupus like symptoms [16] 
Material and Methods Subjects
Peripheral blood samples were obtained from 38 healthy individuals, 18 women and 20 men, at the blood donor centre at the Uppsala University hospital. The mean age of the healthy subjects was 52 years (range 36-71 years). Blood samples from 38 RA patients, 27 women and 11 men, were obtained from the rheumatology unit at the Uppsala University hospital, Sweden. All RA patients had an IgM rheumatoid factor (RF) seropositive disease and were diagnosed according to the American College of Rheumatology [34] . The current treatment regimens included TNF-inhibitors, prednisolon, non-steroid anti-inflammatory drugs and conventional disease-modifying antirheumatic drugs. The mean age of the patients was 59 years (range 33-76 years), the mean age at disease onset was 45 years (range 16-71 years) and the mean disease duration was 14 years (range 1-52 years). The RA patients were also grouped according to disease activity. Patients were defined as having an active disease if they showed clinical signs of acute inflammation in a minimum of one joint while visiting the rheumatology clinic, or having a nonactive disease if they did not show any clinical signs of acute inflammation during the visit. The study was approved by the local ethics committee in Uppsala and informed consent was obtained from all participating subjects.
Peripheral blood mononuclear cell (PBMC) isolation
EDTA-treated venous blood samples were centrifuged for 15 min at 1800 rpm and the plasma was removed. The cells were resuspended in PBS-EDTA (0.2 mM) and then transferred on to a FicollPaque (GE Healthcare, Uppsala, Sweden) layer. The samples were centrifuged for 30 min without brake at room temperature. The interphase, containing PBMC, was collected and washed in PBS-EDTA three times by centrifugation at 1200 rpm for 10 min. The cell concentration was thereafter determined in a Bürker chamber using trypan blue and a light microscope.
Antibody staining and FACS
Twohundred and fifty thousand PBMC were suspended in 100 µl of 1% BSA in PBS and were stained with FITCconjugated mouse anti-human CD19 (clone HD37, Dako, Glostrup, Denmark) in combination with mouse anti-human CR1 conjugated to PE (clone E11, BD Pharmingen), mouse anti-human CR2 conjugated to PE (clone LT21, BioLegend) or anti-human FcγRIIb conjugated with biotin (clone GB3, kindly provided by Dr. U. Jacob, SuppreMol, Martinsried, Germany). All Ab were of mouse IgG1 isotype, and control samples were thus stained with PE-, FITC-or biotin-conjugated mouse IgG1 isotype controls (all from BD Pharmingen). The samples were stained for 25 min at 4˚C in the dark and thereafter washed twice with 1% BSA in PBS for 5 min at 1200 rpm. A second staining with PE-conjugated streptavidin for 25 min at 4˚C in the dark was performed on samples stained with biotin-conjugated antibodies. The lymphocytes were defined in a forward and side scatter diagram and the B cells were further defined by CD19 positive staining. The percentage of cells expressing FcγRIIb, CR1 or CR2 was calculated from the CD19 + B cells. Cells with a higher mean fluorescent intensity (MFI) value than the corresponding isotype control was considered positive.
B cell isolation using MACS
The PBMC were incubated with anti-CD2-biotin for 30 min at 4˚C in the dark. The cells were subsequently washed and stained with magnetic beads conjugated to streptavidin and anti-CD14 labeled magnetic beads according to the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany). The cells were thereafter put on a LS column in a magnetic field and the negative fraction, containing B cells, was collected. The B cell yield was 89 ± 8 %.
B cell proliferation assay
Peripheral blood B cells, purified from 13 RA patients and 15 healthy controls, were suspended in RPMI medium, supplemented with 10% FCS, 10 mM Hepes, 50 µM β-mercaptoethanol, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamin (all from Sigma) and 100 000 cells were plated per well in a 96-well microtiter plate (Nunc, Roskilde Denmark). The B cells were stimulated with IL-2 (10 ng/ml), CpG type B (3 µg/ml) (ODN-2006, HyCult biotechnology, Uden, The Netherlands), F(ab) 2 anti-µ (3 µg/ml) (Fc5µ, Jackson Immunoresearch, West Grove, USA) or IgG anti-µ, (3 µg/ml) (Biodesign International, Saco, USA) in different combinations. All stimulations were at least done in duplicates. The cells were cultured for 6 days at 37°C with 5% CO2, and 1µCi of [ 3 H]-thymidine (Amersham Pharmacia) was added per well during the last 22 h of culture. The plate was harvested using a beta plate 96-well harvester (Wallac/PerkinElmer, Waltham, USA) and [ 3 H]-thymidine incorporation, detected as counts per minute (cpm), was measured using a liquid scintillation counter (β-plate Scint Wallac/PerkinElmer, Waltham, USA). figure 1a-c) . However, the expression value (MFI) of FcγRIIb was significant lower in women than in men (p < 0.05) (figure 1d), while no gender difference in CR1 and CR2 expression observed ( figure 1e-f) . We have previously reported that the expression of CR1, but not CR2, on B cells is decreased with increasing age in women, an effect not seen in men [31] . This also seems to be true for FcγRIIb, as lower receptor expression correlated with increasing age in women, but not in men (r 2 = 0.27, p = 0.03 and r 2 = 0.01, p =0.66 respectively) (Figure 1g-h) . As estrogen levels drop in middle aged women these data may imply that estrogen retains inhibitory receptor expression on B cells in women.
Reduced FcγRIIb, CR1 and CR2 on B cells in RA We analyzed the expression of FcγRIIb, CR1 and CR2 on CD19 + B cells from RA patients in comparison with healthy controls. We found that RA patients had significant lower numbers of FcγRIIb expressing B cells compared to healthy controls (p < 0.05) ( figure 2a) . Furthermore, the numbers of B cells expressing CR1 and CR2 were also reduced in RA patients compared to healthy individuals (CR1; p < 0.001 CR2; p < 0.01) (figure 2b-c). When analyzing the receptor expression on the B cells, we observed a decrease in FcγRIIb in the RA patients compared to the healthy controls (p < 0.05) ( figure  2d ). An even more pronounced reduction of receptor expression was observed for CR1 and CR2 in RA B cells compared to healthy controls (CR1, CR2; p < 0.001) ( figure 2e-f) . These data clearly demonstrate that RA B cells have poor Fc and CR expression.
Disease activity does not correlate with low receptor expression on B cells
To investigate if the reduced FcγRIIb, CR1 and CR2 expression on RA CD19 + B cells was associated with disease activity we grouped the RA patients according to disease status as described in the material and methods. However, low receptor expression was not associated with disease activity, as both active and non-active RA patients displayed similar receptor expression ( figure 3a-c) . Increased BCR-independent B cell proliferation in RA We explored whether the lower receptor expression on RA CD19 + B cells affected the proliferation capacity of the cells. Thus, B cells from RA patients and healthy controls were stimulated with IL-2 alone, or with IL-2 in combination with CpG, IgG anti-µ or with F(ab) 2 anti-µ. A comparable spontaneous B cell proliferation (without any stimuli added) was observed in RA patients and healthy controls (Figure 4a) . However, when the B cells were stimulated with IL-2, the B cells from the RA patients proliferated 4.5 times more than those from the healthy controls (p < 0.05) (Figure 4b) . In order to rule out that this was due to contamination by T cells, the correlation between B cell impurity and IL-2 proliferation was calculated. No significant correlation was seen (data not shown), implying that T cell contamination do not account for the increased proliferation of IL-2 in the RA patients. Furthermore, when the cells were stimulated with IL-2 + CpG, IL-2 + CpG + IgG anti-µ or IL-2 + CpG + F(ab) 2 anti-µ no differences were observed between patients and healthy individuals (Figure 4c-e) . However, we observed that the B cells from healthy individuals proliferated more frequently with IL-2 + CpG than when stimulated with IL-2 alone (7269 and 360 mean cpm, respectively; 20-fold increase) (p < 0.01), whereas the addition of CpG to IL-2 stimuli did not significantly increase the proliferation of RA B cells [47] . Thus, antigen-bound B cells stimulated with IL-2 become activated and proliferate, while naïve B cells do not, supporting the idea that B cells from RA patients have already bound antigen in vivo [48] . Further, the proliferation mediated by IL-2 (without any further BCR engagement) suggests that RA B cells can become activated by any nearby activated T cell accompanied by IL-2 production, a process known as bystander activation [49] . TLR-9 has been found to contribute to the activation of RF positive B cells [50; 51] , however, we found that the RA B cells had decreased proliferation to the TLR-9 ligand CpG compared to B cells from healthy subjects. This finding might be due to differences in intracellular signaling, or insufficient ligand uptake to the endosomal-located TLR-9. Recent studies by Chaturvedi et al. demonstrated that CpG uptake is associated with BCR ligation, and CR2 have been shown to influence BCR internalization [52; 53; 54] . It is therefore possible that the hyporesponse to the TLR9-ligand seen in RA patients might be associated with the lower expression of CR2, resulting in less efficient CpG internalization via BCR to the TLR.
In conclusion, our findings demonstrate that B cells from RA patients have significantly lower levels of the inhibitory receptors FcγRIIb and CR1 together with the activating CR2. This modified expression is likely contributing to a break of tolerance leading to dysregulated B cells that generate auto-antibodies and autoimmunity. The low FcγRIIb expression in healthy women that even decreases with age, is likely a contributing factor to the increased susceptibility to RA in women.
